BioMedNewsBreaks

MondayMar 01, 2021 1:19 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for March Investor Conferences

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its plans to participate in two virtual investor conferences in the month of March. These include the Sachs 14th Annual European Life Sciences CEO Forum taking place March 10-12, as well as the 33rd Annual Roth Conference scheduled to be held from March 15-17, 2021. The company’s president and CEO, Rodney Varner, will lead Genprex’s presentations and will be available for one-on-one meetings with investors throughout the conferences. Interested parties should visit https://ibn.fm/MUouk and https://ibn.fm/J1qLh to register. The presentations will…

Continue Reading

MondayMar 01, 2021 12:07 pm

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Releases Update on Promotional and Marketing Activity Comments

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has provided an update to its Jan. 22, 2021, press release regarding recent promotional and investor relations. The updated comments were made at the request of IIROC and the Canadian Securities Exchange ("CSE"). The comments are specifically in regard to a newsletter published by WallStreetAlerts, on behalf of the company. In addition to the updated comments, the company reminded investors that the best source for full disclosure about the company is the company itself, as well as SEDAR…

Continue Reading

MondayMar 01, 2021 10:39 am

BioMedNewsBreaks – PlantX Life Inc. (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF) Announces Results of Annual and Special Meeting

PlantX Life (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF), a multifaceted marketplace providing consumers all things plant based, has released results of its recent annual and special shareholder meeting. The meeting was held Feb. 26, 2021, and during the meeting, shareholders nominated and elected five board members: Quinn Field-Dyte, Lorne Rapkin, Peter Simeon, Alex Hoffman and Ralph Moxness. The company noted that incumbent director Todd Shapiro did not seek re-election at the meeting. Alex Hoffman and Ralph Moxness were elected to the board of directors for the first time. During the course of the meeting, shareholders passed all other motions on the agenda, including fixing the number of directors of…

Continue Reading

MondayMar 01, 2021 9:26 am

BioMedNewsBreaks – Grey Cloak Tech Inc. (GRCK) Changes Name, Ticker; Now Healthy Extracts Inc.

Grey Cloak Tech (OTCQB: GRCK) has announced that the company has officially changed its name to Healthy Extracts Inc. The company’s ticker will also change to OTCQB: HYEX. These changes are official today, March 1, 2021. The company is focused on the development of its proprietary natural plant-based formulations; the company is also committed to sales and distribution of cardiovascular and neuro products. Grey Cloak, now Healthy Extracts, has two subsidiaries: Ultimate Brain Nutrients, a science-based company that develops unique, plant-based, high-quality, neuro-products that increase brain health including memory, cognition, focus and neuro-energy; and BergaMet NA, a provider of nutraceutical…

Continue Reading

FridayFeb 26, 2021 2:06 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Looks to AI to Improve Clinical Decision Making for Ovarian Cancer Patients

Predictive Oncology (NASDAQ: POAI), through its wholly owned subsidiary, Helomics, has sought to end the alarming statistics surrounding ovarian cancer. According to figures provided by the American Cancer Society and quoted by an article discussing POAI’s motivations and operations, “an estimated 21,750 women received a new diagnosis of ovarian cancer this year (2020), and almost 14,000 women will die from the disease. Those numbers make ovarian cancer the fifth-leading cause of cancer deaths in women.” In a bid to change this reality, Predictive Oncology, a company that focuses on using data and artificial intelligence to develop personalized cancer therapies, has…

Continue Reading

ThursdayFeb 25, 2021 3:18 pm

BioMedNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) i/Blue Imaging(TM) Technology Holds Potential Across Multiple Endoscopic Procedures

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is focused on changing the standards of visualizing cancer during minimally invasive procedures. The company’s innovative technology has the potential to revolutionize the current standard of care for bladder cancer patients. Imagin Medical’s i/Blue Imaging(TM) System is based on advanced optics and light sensors and uses patented ultrasensitive imaging technology. The state-of-the-art control unit features a dual-wavelength light source, two-channel camera control and data recorder. Simultaneous white and blue light illumination of the bladder allows for side-to-side image monitoring and better visualization of tumors and margins. A recent article discussing…

Continue Reading

ThursdayFeb 25, 2021 1:00 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Progress Toward Upcoming Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today confirmed that the clinical program for Berubicin is on track to start enrolling patients in March 2021. CNS' lead product candidate, Berubicin, is a novel anthracycline and the first anthracycline to cross the blood-brain barrier and is in development for the treatment of a number of serious brain and CNS oncology indications. The upcoming, potentially pivotal study will evaluate the efficacy of Berubicin in the treatment of adult glioblastoma multiforme (“GBM”), one of…

Continue Reading

WednesdayFeb 24, 2021 10:45 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enters Agreement for Upcoming Berubicin Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (8SV1.F) (“WPD”), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, have entered into an agreement for WPD to obtain Investigational Medicinal Product (“IMP”) classification for Berubicin for its use in upcoming  clinical trials. According to the update, WPD will purchase half of the batch previously manufactured for CNS by BSP Pharmaceuticals for the WPD-201 and WPD-201P studies, planned to begin in the first half of 2021. Berubicin is a novel anthracycline candidate for the treatment of a number…

Continue Reading

WednesdayFeb 24, 2021 10:15 am

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) Announces Receipt of Regulatory Approval Powdery Mildew Bio-Fungicide in Canada

MustGrow Biologics (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, has received regulatory approval from Canada’s Pest Management Regulatory Agency (“PMRA”) for use of a powdery mildew bio-fungicide product; the approval covers use of the powdery mildew bio-fungicide suppression treatment on cannabis and hemp products. MustGrow announced more than a year ago that it had completed a definitive licensing agreement to obtain the exclusive treatment from a leading multinational biological and microbial company. The bio-fungicide product, which is not mustard derived, like MustGrow’s other products, is designed to…

Continue Reading

WednesdayFeb 24, 2021 10:11 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces First Order for Rapid COVID-19 Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has placed an initial order for rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system. The test systems, known as COVID-ID Labs, were ordered from XPhyto’s exclusive diagnostic development partner, 3a-diagnostics GmbH ("3a"). The first order consists of 9,600 individual tests; the tests are packaged in 200 kits of 48 tests each. The tests, which should arrive by mid-March 2021, will be used as samples for review and evaluation and will be primarily given to prospective distribution partners and licensees…

Continue Reading